This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Spectral MD Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Spectral MD Holdings.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.6%
Wachstumsrate der Einnahmen	62.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	11 Sep 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

DB:0HB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	118	N/A	N/A	N/A	1
12/31/2024	42	N/A	N/A	N/A	1
12/31/2023	26	N/A	N/A	N/A	1
3/31/2023	25	-6	-4	-4	N/A
12/31/2022	25	-3	-1	-1	N/A
9/30/2022	23	-3	-1	-1	N/A
6/30/2022	20	-4	-2	-2	N/A
3/31/2022	18	-5	-3	-3	N/A
12/31/2021	15	-5	-3	-3	N/A
9/30/2021	16	-4	0	0	N/A
6/30/2021	17	-3	2	2	N/A
3/31/2021	17	-1	3	3	N/A
12/31/2020	17	1	4	4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Insufficient data to determine if 0HB's forecast earnings growth is above the savings rate (0.4%).

Ertrag vs. Markt: Insufficient data to determine if 0HB's earnings are forecast to grow faster than the German market

Hohe Wachstumserträge: Insufficient data to determine if 0HB's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: 0HB's revenue (62.1% per year) is forecast to grow faster than the German market (3.7% per year).

Hohe Wachstumseinnahmen: 0HB's revenue (62.1% per year) is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if 0HB's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Spectral MD Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Spectral MD Holdings, Ltd. Provides Guidance of Revenue and Loss for the Year

Spectral MD Holdings, Ltd. Provides Earnings Guidance for the Year Ended 31 December 2021

Recent updates

Spectral MD Holdings, Ltd. (AIM:SMD) completed the acquisition of Rosecliff Acquisition Corp I (NasdaqCM:RCLF) from Rosecliff Acquisition Sponsor I LLC and others in a reverse merger transaction.

Spectral MD Holdings' Admission to Trading of Ordinary Shares on AIM To Be Cancelled on 8 September 2023

Spectral MD Holdings, Ltd., Annual General Meeting, Aug 31, 2023

Full year 2022 earnings released: US$0.021 loss per share (vs US$0.054 loss in FY 2021)

Spectral MD Holdings, Ltd. to Report Fiscal Year 2022 Results on Feb 27, 2023

Spectral MD Holdings, Ltd. Provides Guidance of Revenue and Loss for the Year

High number of new and inexperienced directors

Spectral MD Holdings, Ltd. Announces Appointment of Niko Pagoulatos as Chief Operating Officer

Spectral MD Holdings, Ltd. Announces Erich Spangenberg, Non-Executive Director, to Resign as A Director, Effective October 31St 2022

First half 2022 earnings released: US$0.005 loss per share (vs US$0.016 loss in 1H 2021)

Spectral MD Holdings, Ltd. to Report First Half, 2022 Results on Sep 19, 2022

Spectral MD Holdings, Ltd., Annual General Meeting, Sep 27, 2022

Spectral MD Holdings, Ltd. Announces Start of its Clinical Validation Study to Support the Development of its Diabetic Foot Ulcer Application for theDeepView Wound Imaging System

Spectral MD Holdings, Ltd. Provides Earnings Guidance for the Year Ended 31 December 2021

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken